Northstar Group’s AbbVie ABBV Stock Holding History

Northstar Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.98M	Sell	22,876 -1,460	-6%	-$324K	0.7%	31
2025 Q4	$5.56M	Buy	24,336 +15,875	+188%	+$3.62M	0.76%	31
2025 Q3	$1.96M	Sell	8,461 -62	-0.7%	-$12.6K	0.29%	51
2025 Q2	$1.58M	Buy	8,523 +11	+0.1%	+$2.04K	0.24%	55
2025 Q1	$1.78M	Buy	8,512 +58	+0.7%	+$11.3K	0.29%	51
2024 Q4	$1.5M	Sell	8,454 -31	-0.4%	-$5.7K	0.25%	52
2024 Q3	$1.68M	Sell	8,485 -100	-1%	-$18.7K	0.29%	51
2024 Q2	$1.47M	Hold	8,585	–	–	0.28%	51
2024 Q1	$1.56M	Hold	8,585	–	–	0.31%	56
2023 Q4	$1.33M	Sell	8,585 -70	-0.8%	-$10.2K	0.29%	57
2023 Q3	$1.29M	Sell	8,655 -118	-1%	-$17.3K	0.31%	56
2023 Q2	$1.18M	Buy	8,773 +100	+1%	+$14.7K	0.28%	59
2023 Q1	$1.38M	Hold	8,673	–	–	0.35%	57
2022 Q4	$1.4M	Sell	8,673 -175	-2%	-$26.8K	0.4%	54
2022 Q3	$1.19M	Hold	8,848	–	–	0.36%	59
2022 Q2	$1.35M	Sell	8,848 -212	-2%	-$32.4K	0.39%	57
2022 Q1	$1.47M	Sell	9,060 -86	-0.9%	-$12.5K	0.35%	59
2021 Q4	$1.24M	Sell	9,146 -28	-0.3%	-$3.31K	0.3%	64
2021 Q3	$989K	Sell	9,174 -65	-0.7%	-$7.43K	0.26%	70
2021 Q2	$1.04M	Buy	9,239 +85	+0.9%	+$9.57K	0.27%	68
2021 Q1	$991K	Buy	9,154 +41	+0.4%	+$4.38K	0.28%	67
2020 Q4	$976K	Buy	9,113 +9	+0.1%	+$865	0.3%	64
2020 Q3	$797K	Buy	9,104 +10	+0.1%	+$941	0.27%	69
2020 Q2	$893K	Sell	9,094 -74	-0.8%	-$6.51K	0.36%	61
2020 Q1	$698K	Buy	9,168 +9	+0.1%	+$767	0.32%	63
2019 Q4	$811K	Buy	9,159 +10	+0.1%	+$830	0.31%	66
2019 Q3	$693K	Sell	9,149 -173	-2%	-$11.9K	0.29%	71
2019 Q2	$678K	Buy	9,322 +9	+0.1%	+$707	0.29%	72
2019 Q1	$750K	Sell	9,313 -390	-4%	-$31.9K	0.33%	71
2018 Q4	$895K	Sell	9,703 -208	-2%	-$18.3K	0.46%	53
2018 Q3	$937K	Sell	9,911 -93	-0.9%	-$8.82K	0.43%	57
2018 Q2	$927K	Buy	10,004 +6	+0.1%	+$586	0.47%	55
2018 Q1	$946K	Sell	9,998 -183	-2%	-$20.1K	0.49%	54
2017 Q4	$985K	Buy	10,181 +292	+3%	+$27.5K	0.52%	52
2017 Q3	$879K	Sell	9,889 -38	-0.4%	-$2.89K	0.51%	53
2017 Q2	$720K	Buy	9,927 +6	+0.1%	+$403	0.44%	61
2017 Q1	$645K	Sell	9,921 -33	-0.3%	-$2.08K	0.43%	61
2016 Q4	$623K	Buy	9,954 +6	+0.1%	+$366	0.43%	58
2016 Q3	$627K	Sell	9,948 -243	-2%	-$15.7K	0.45%	58
2016 Q2	$631K	Buy	10,191 +5	+0%	+$305	0.47%	58
2016 Q1	$582K	Sell	10,186 -193	-2%	-$10.8K	0.44%	60
2015 Q4	$615K	Buy	10,379 +714	+7%	+$41.1K	0.49%	57
2015 Q3	$540K	Hold	9,665	–	–	0.44%	61
2015 Q2	$649K	Hold	9,665	–	–	0.5%	59
2015 Q1	$566K	Sell	9,665 -400	-4%	-$24.2K	0.44%	63
2014 Q4	$659K	Buy	+10,065	New	+$635K	0.52%	56

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northstar Group's ABBV Position: Q1 2026 in Review

Northstar Group reduced its AbbVie (ABBV) stake by 6% in Q1 2026, selling an estimated $324K and leaving 22,876 shares worth $4.98M. The position accounts for 0.7% of the portfolio, ranked #31.

Northstar Group first reported a position in ABBV in Q4 2014 and has held it in 46 quarters since. The position peaked at $5.56M in Q4 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Northstar Group held 22,876 shares of AbbVie worth $4.98M as of Q1 2026.
Northstar Group sold 1,460 AbbVie shares in Q1 2026, an estimated $324K.
AbbVie made up 0.7% of Northstar Group's portfolio in Q1 2026, its #31 holding.
Northstar Group first reported a position in AbbVie in Q4 2014 and has held it in 46 quarters since.
Northstar Group's AbbVie position peaked at $5.56M in Q4 2025.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Northstar Group's 13F filing for Q1 2026, filed 28 Apr 2026.